N
Nael Martini
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 147
Citations - 13911
Nael Martini is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Lung cancer & Carcinoma. The author has an hindex of 63, co-authored 147 publications receiving 13578 citations. Previous affiliations of Nael Martini include Washington University in St. Louis & Cornell University.
Papers
More filters
Journal ArticleDOI
Multiple primary lung cancers.
Nael Martini,Myron R. Melamed +1 more
TL;DR: The problems involved in establishing the diagnosis of multiple primary lung cancers, the choice of treatment, and the expectation for survival are discussed.
Journal ArticleDOI
Incidence of local recurrence and second primary tumors in resected stage I lung cancer
Nael Martini,Manjit S. Bains,Michael E. Burt,Maureen F. Zakowski,Patricia M. McCormack,Valerie W. Rusch,Robert J. Ginsberg +6 more
TL;DR: Three facts emerge as significant: (1) Systematic lymph node dissection is necessary to ensure that the disease is accurately staged; (2) lesser resections (wedge/segment) result in high recurrence rates and reduced survival regardless of histologic type; and (3) second primary lung cancers are prevalent in long-term survivors.
Journal ArticleDOI
The role of surgery in N2 lung cancer.
Nael Martini,Betty J. Flehinger +1 more
TL;DR: Data is presented to support the view that a significant number of patients with mediastinal lymph node metastases do have resectable tumors with encouraging long-term survival results and steps identified to guide the physicians in selecting the patients who can benefit from this surgical approach.
Journal ArticleDOI
Thymoma: A multivariate analysis of factors predicting survival
David Blumberg,Jeffrey L. Port,Benny Weksler,Ruby Delgado,Juan Rosai,Manjit S. Bains,Robert J. Ginsberg,Nael Martini,Patricia M. McCormack,Valerie W. Rusch,Micahel E. Burt +10 more
TL;DR: Patients with stage I disease require no further therapy after complete surgical resection and neoadjuvant therapy should be considered for patients with large tumors and invasive disease.
Journal ArticleDOI
Preoperative chemotherapy for stage IIIa (N2) lung cancer: the Sloan-Kettering experience with 136 patients.
Nael Martini,Mark G. Kris,Betty J. Flehinger,Richard J. Gralla,Manjit S. Bains,Michael E. Burt,Robert T. Heelan,Patricia M. McCormack,Katherine M.W. Pisters,James R. Rigas,Valerie W. Rusch,Robert J. Ginsberg +11 more
TL;DR: It is demonstrated that preoperative chemotherapy with MVP produces high response rates in stage IIIa (N2) disease, high complete resection rates occur after response to chemotherapy, and survival is longest in patients who have acomplete resection after major response to chemo.